LETTER TO THE EDITOR

Drug classification for patients with comorbidities

Farid Belialov*

The development of new effective drugs along with population aging has led to a high number of patients with two or more chronic diseases. In the presence of multiple comorbidities, a drug selection is a difficult task for physicians. When choosing drugs, one should take into account the possible impact of treatment on comorbid diseases, which can be positive or negative (Table 1). In addition, polypharmacy can lead to various drug-induced disorders and drug–drug interactions. The long lists of contraindications, warnings, and precautions in drug instructions pose difficulties for physicians to select optimal drugs for the treatment of patients with comorbidities.

Classification systems uniting items with similar features are useful for practical purposes. Drug classifications with the positive and negative labeling had been developed for specific patient populations or clinical settings. For instance, drug selection in pregnant women which is based on the FDA classification system and divides all drugs into classes A, B, C, D, and X depending on the risk to the fetus and newborn. The FDA not supported this classification from 2015, but its modifications are used until now in a few countries. FORTA list which combines positive and negative labeling (A, B, C, and D) of medications chronically prescribed to older patients had been proposed to reduce polypharmacy [1]. The Arizona Center for Education and Research on Therapeutics (AzCERT) maintains the drug list that has a risk of QT prolongation and cardiac arrhythmias. This classification divides drugs into groups with conditional, possible, known and high risk of malignant arrhythmias.

In this paper, it is suggested to rate the effects of drugs on comorbidities as favorable, possible, neutral, undesirable, and unfavorable (Table 2). In addition, these drug classes can be labelled as A, B, C, D, and X. Classification systems mentioned above can be integrated into the FORCOM (Fit FOR COMorbidity) universal drug classification system which will be include the effects of different drugs on comorbidities. Besides, due to the specific and multidirectional drug–disease interactions, it will be require descriptions and commentaries for practice use.

The paucity of randomized trials in patients with overt comorbidities makes it difficult to develop drug classifications. Patients with severe comorbidities are generally excluded from trials to allow more objective investigations of drugs and to reduce the number of adverse effects. Unfortunately, subgroup analyses of randomized clinical trials are not reliable. Information on drug classification is mainly based on observational studies and registries.

An example of the FORCOM classification coronary artery disease medication in patients with liver cirrhosis is presented in Table 3. Decompensation of cirrhosis is prevented by nonselective β-blockers (nadolol, propranolol, and carvedilol) which are recommended for the primary and secondary prevention of bleeding [2, 3]. The beta1-blockers and isosorbide mononitrate can reduce portal pressure [4]. Statins are associated with a lower risk of hepatic decompensation and mortality in patients with chronic liver diseases and liver cirrhosis [5, 6]. On the other hand, antiplatelet therapy can increase the risk

*Correspondence: fbelyalov@gmail.com

Department of Gerontology, Geriatrics, and Clinical Pharmacology, Russian Medical Academy of Continuous Professional Education, Yubileiny 100/4, Irkutsk 664079, Russia

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of bleeding in patients with vitamin K-dependent coagulopathies, thrombocytopenia, esophageal varices, and gastric ulcers. Ranolazine is contraindicated in patients with liver cirrhosis, due to the increase of $C_{\text{max}}$ (maximum serum concentration) by 80% in cirrhotic patients with moderate hepatic impairment. Furthermore, the risk of long QT interval rises threefold. Rivaroxaban should not be used in patients with Child–Pugh class B liver cirrhosis because of increase the drug exposure more than twice [7, 8].

The FORCOM classification of psychopharmacological drugs in patients with coronary artery disease is shown in Table 4. Antidepressants and anxiolytics are used in patients with coronary artery disease to treat depressive and anxiety disorders reducing the quality of life to a greater extent than the somatic diseases. The medications with the lowest cholinolytic, arrhythmogenic, and hemodynamic adverse effects are usually selected for patients with coronary artery disease. The safety of selective serotonin reuptake inhibitors (sertraline, citalopram, and escitalopram) and mirtazapine were confirmed in patients after myocardial infarction by reliable studies [9–11]. Sertraline which is the most studied in randomized trials drug have a weak effect on QT interval than citalopram and escitalopram, and fewer interactions with proton pump inhibitors than escitalopram [12, 13].

### Table 1 Effect of drugs on comorbid diseases

| Drugs          | Diseases             | CAD | Hypertension | AF | Diabetes | CKD | Heart failure | Cirrhosis |
|----------------|----------------------|-----|--------------|----|----------|-----|---------------|-----------|
| ACEI, ARB      | +                    | +   | +            | +  | +        | +   | +             | +         |
| Aldosterone antagonists | +                |     | +            |   | +        | +   | +             | +         |
| Beta-blockers  | ++                   | ++  | +            | ++ | +        | ++  | +             | +         |
| Ranolazine     | ++                   | ++  | +            | +  | +        |     | +             | +         |
| Statins        | +                    | +   | ++/-         | +  | +        |     | +             |           |
| Metformin      | +                    | +   | +/-          | ++ | +        |     | +             |           |
| SGLT2          | +                    | +   | +            | +  | +        |     | +             | +         |

ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blockers, CAD coronary artery disease, CKD chronic kidney disease, SGLT2 sodium–glucose cotransporter 2 inhibitors, + + favourable effect, + possible effect, − undesirable effect, − − unfavourable effect.

### Table 2 FORCOM drug classification according to influence on comorbid diseases

| Class | Drug’s effect | Influence on comorbid disease |
|-------|---------------|-------------------------------|
| A     | Favourable    | Drugs with pronounced positive effects |
| B     | Possible      | Drugs may have a mild positive effects |
| C     | Neutral       | Drugs without any significant effect or contradictory effect on comorbid disease |
| D     | Undesirable   | Drugs with possible rare non-severe adverse effects or unexplored drugs |
| X     | Unfavourable  | Drugs with high incidence (≥ 1%) of severe adverse effects |

### Table 3 FORCOM drug classification for treatment of coronary artery disease in patients with liver cirrhosis

| Class | Drugs |
|-------|-------|
| A     | Nonselective beta-blockers (nadolol, propranolol, carvedilol) |
| B     | Beta1-blockers, isosorbide mononitrate, statins |
| C     | Calcium antagonists, molsidomine, nitrates, nicorandil, trimetazidine |
| D     | Antiplatelets |
| X     | Ranolazine, rivaroxaban |

### Table 4 FORCOM drug classification for treatment of mental disorders in patients with coronary artery disease

| Class | Drugs |
|-------|-------|
| C     | Benzodiazepines, selective serotonin reuptake inhibitors, mirtazapine, trazodone |
| D     | Antipsychotics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, mianserin, trazodone |
| X     | Tricyclic antidepressants |
Treatment of depression with escitalopram reduced the risk of cardiac events in the randomized EsDEPACS trial including 300 patients after acute coronary syndrome [14].

It must be taken into account that selective serotonin reuptake inhibitors increase the risk of bleeding in patients taking these drugs combined with aspirin or dual antiplatelet therapy [15, 16]. Venlafaxine is associated with some undesirable cardiovascular effects, including hypertension and orthostatic hypotension [17]. The effect of monoamine oxidase inhibitors, mianserin, and trazodone in patients with coronary artery disease has not been established. Tricyclic antidepressants are contraindicated in patients with heart diseases due to cardiac adverse effects, including sinus tachycardia, postural hypotension, and electrophysiological changes (prolongation of QRS, PR, and QT intervals) even at therapeutic dosages. There are conflicting estimates of the relationship between antipsychotics and the risk of myocardial infarction [18, 19]. It should be taken into account that antipsychotics may increase the risk of ventricular tachyarrhythmias and sudden cardiac arrest [20, 21].

In this article, we are the first to highlight the common principles of the drug classification system. Due to the lack of reliable studies, the attribution of drugs to one class or another may be debated and improved.

Therefore, the FORCOM classification system may be useful to make consistent the positive and negative effects of drugs on comorbidities, to unify the existing narrow classifications, to compare different expert opinions, to simplify available information in clinical guidelines, and to help practitioners in the selection of efficacious and safe drugs for patients with multiple comorbidities.

Author contributions
The author confirms sole responsibility for the following: study conception and design, data collection, analysis and interpretation of results, and manuscript preparation. The author read and approved the final manuscript.

Funding
None.

Declarations

Competing interests
The authors declare that they have no competing interests.

Received: 23 August 2022 Accepted: 17 September 2022 Published online: 22 September 2022

References
1. Pazan F, Weiss C, Wehling M, et al. The EURO-FORTA (Fit FOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging. 2018;33(1):61–71. https://doi.org/10.1007/s40266-017-0514-2.
2. Villanueva C, Albillos A, Genesca J, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2019;10181:1597–608. https://doi.org/10.1016/S0140-6736(18)31875-0.
3. Shi KQ, Liu WY, Pan ZZ, et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. Eur J Clin Invest. 2013;43(8):844–54. https://doi.org/10.1111/eji.12115.
4. Bihari D, Westaby D, Cimason A, et al. Reductions in portal pressure by selective beta-2-adrenoceptor blockade in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol. 1984;17(6):753–7.
5. Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521–1530.e8. https://doi.org/10.1016/j.cgh.2017.04.039.
6. Gu Y, Yang X, Liang H, Li D. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231. https://doi.org/10.1186/s12876-019-1147-1.
7. Steffel J, Collins R, Antz M, et al. European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23:1612–76. https://doi.org/10.1093/europace/euaa065.
8. Kubitz D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89–98. https://doi.org/10.1111/bcp.12054.
9. Honig A, Kusper AM, Schene AH, et al. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606–13. https://doi.org/10.1097/PSY.0b013e318142b260d.
10. Zuidersma M, Conradi HJ, van Melle JP, et al. Depression treatment after myocardial infarction and long-term risk of subsequent cardiovascular events and mortality: a randomized controlled trial. J Psychosom Res. 2013;74(1):25–33. https://doi.org/10.1016/j.jpsychores.2012.08.015.
11. Kim J-M, Kang H-J, Bae K-Y, et al. Determinants and escitalopram treatment effects on suicidal ideation in patients with acute coronary syndrome: findings from the K-DEPACS and EsDEPACS studies. Int J Cardiol. 2016;219:225–30. https://doi.org/10.1016/j.ijcard.2016.06.048.
12. Hanash JA, Hansen BH, Hansen JF, et al. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2012;60(4):397–405. https://doi.org/10.1097/FJC.0b013e3182767704.
13. Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit. 2015;37(1):90–7. https://doi.org/10.1097/FTD.0000000000000101.
14. Kim J, Stewart R, Lee Y, et al. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome. A randomized clinical trial. JAMA. 2018;320(4):350–8. https://doi.org/10.1001/jama.2018.08017.
15. Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32. https://doi.org/10.1016/j.phrs.2016.08.017.
16. Nochaiwong S, Rungorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80–97. https://doi.org/10.1080/07853890.2021.197474.
17. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry. 2006;14(9):796–802. https://doi.org/10.1097/01.JGP.0000204328.51015.b3.
18. Živkovic S, Koh CH, Kaza N, Jackson CA. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psychiatry. 2019;19(1):189. https://doi.org/10.1186/s12888-019-2177-5.
19. Yu ZH, Jang HY, Shao L, et al. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):624–32. https://doi.org/10.1111/bcp.12985.

20. Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: a meta-analysis of observational studies. Clin Pharmacol Ther. 2016;99(3):306–14. https://doi.org/10.1002/cpt.250.

21. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc. 2015. https://doi.org/10.1161/JAHA.114.001568.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.